Naples Prognostic Score as an Independent Predictor of Survival Outcomes for Resected Locally Advanced Non-Small Cell Lung Cancer Patients After Neoadjuvant Treatment

被引:7
|
作者
Zou, Zhonghua [1 ]
Li, Jinping [2 ]
Ji, Xiang [2 ]
Wang, Tingxing [1 ]
Chen, Qingqing [1 ]
Liu, Zhengcao [1 ]
Ji, Shengjun [1 ,3 ]
机构
[1] Nanjing Med Univ, Gusu Sch, Dept Radiotherapy & Oncol, Affiliated Suzhou Hosp, Suzhou, Peoples R China
[2] Fangzi Peoples Hosp, Dept Gastroenterol, Weifang, Peoples R China
[3] Nanjing Med Univ, Gusu Sch, Dept Radiotherapy & Oncol, Affiliated Suzhou Hosp, 16 Baita Rd, Suzhou 215001, Peoples R China
关键词
surgery; locally advanced NSCLC; NPS; prognosis; neoadjuvant treatment; SYSTEMIC INFLAMMATORY RESPONSE; C-REACTIVE PROTEIN; VALIDATION; PARAMETERS; DIAGNOSIS; SURGERY; ALBUMIN; TUMOR;
D O I
10.2147/JIR.S401446
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The Naples Prognostic Score (NPS) can reflect patient's nutritional and inflammatory status, which is identified as a prognostic indicator for various malignant tumors. However, its significance in patients with resected locally advanced non-small cell lung cancer (LA-NSCLC) patients who receive neoadjuvant treatment remains unclear so far.Methods: A total of 165 LA-NSCLC patients surgically treated from May 2012 to November 2017 were retrospectively investigated. The LA-NSCLC patients were divided into three groups according to NPS scores. The receiver operating curve (ROC) analysis was performed to reveal the discriminatory ability of NPS and other indicators for predicting the survival. The NPS and clinicopathological variables were further evaluated the prognostic value by univariate and multivariate Cox analysis.Results: The NPS was related to age (P = 0.046), smoking history (P = 0.004), Eastern Cooperative Oncology Group (ECOG) score (P = 0.005), and adjuvant treatment (P = 0.017). Patients with high NPS scores had worse overall survival (OS) (group 1 vs 0, P = 0.006; group 2 vs 0, P < 0.001) and disease-free survival (DFS) (group 1 vs 0, P < 0.001; group 2 vs 0, P < 0.001). The ROC analysis demonstrated that NPS had better predictive ability than other prognostic indicators. Multivariate analysis revealed that NPS was independent prognostic indicator of OS (group 1 vs 0, hazard ratio [HR] =2.591, P = 0.023; group 2 vs 0, HR = 8.744, P = 0.001) and DFS (group 1 vs 0, HR =3.754, P < 0.001; group 2 vs 0, HR = 9.673, P < 0.001).Conclusion: The NPS could be an independent prognostic indicator in patients with resected LA-NSCLC receiving neoadjuvant treatment and more reliable than the other nutritional and inflammatory indicators.
引用
收藏
页码:793 / 807
页数:15
相关论文
共 50 条
  • [1] A Prognostic Score for Patients Receiving Multimodal Treatment for Locally-Advanced Non-Small Cell Lung Cancer
    Taugner, J.
    Roengvoraphoj, O.
    Kasmann, L.
    Petruknov, O.
    Gennen, K.
    Reem, A.
    Dantes, M.
    Eze, C.
    Belka, C.
    Manapov, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S859 - S859
  • [2] NEOADJUVANT TREATMENT IN LOCALLY ADVANCED NON-SMALL CELL LUNG-CANCER
    FABER, LP
    BONOMI, PD
    SEMINARS IN SURGICAL ONCOLOGY, 1990, 6 (05): : 255 - 262
  • [3] Heart Dose Is an Independent Dosimetrie Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer
    Speirs, Christina K.
    DeWees, Todd A.
    Rehman, Sana
    Molotievschi, Alerson
    Velez, Maria A.
    Mullen, Daniel
    Fergus, Sandra
    Trovo, Marco
    Bradley, Jeffrey D.
    Robinson, Cliff G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 293 - 301
  • [4] Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
    Dai, Jie
    Zhu, Xinsheng
    Li, Dianke
    Huang, Yan
    Liu, Xiaogang
    He, Wenxin
    Duan, Liang
    Zhao, Deping
    Zhu, Yuming
    Chen, Chang
    Provencio, Mariano
    Ramirez, Robert A.
    Antonoff, Mara B.
    Wu, Chunyan
    Jiang, Gening
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (02) : 188 - 200
  • [5] Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
    Pan, Mingmei
    Zhao, Yun
    He, Jianbo
    Wu, Huanqiong
    Pan, Yujia
    Yu, Qitao
    Zhou, Shaozhang
    JOURNAL OF CANCER, 2021, 12 (08): : 2395 - 2402
  • [6] Treatment of locally advanced non-small cell lung cancer - neoadjuvant or adjuvant chemotherapy
    Vokes, Everett E.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S237 - S237
  • [7] Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer
    Ebinc, Senar
    Oruc, Zeynep
    Kalkan, Ziya
    Teke, Fatma
    Onat, Serdar
    Urakci, Zuhat
    Kaplan, Muhammet Ali
    Kucukoner, Mehmet
    Isikdogan, Abdurrahman
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [8] Clinical Significance of Preoperative Naples Prognostic Score in Patients With Non-Small Cell Lung Cancer
    Ren, Dahu
    Wu, Wenbo
    Zhao, Qingtao
    Zhang, Xiaopeng
    Duan, Guochen
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [9] Neoadjuvant Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Nakagawa, Taku
    Minamiya, Yoshihiro
    Saito, Hajime
    Imai, Kazuhiro
    Konno, Hayato
    Kudo, Satoshi
    Saito, Yoshitaro
    Kurihara, Nobuyasu
    Watanabe, Shinnosuke
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S685 - S686
  • [10] Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
    Bergamino, Milana
    Rullan, Antonio J.
    Saigi, Maria
    Peiro, Inmaculada
    Montanya, Eduard
    Palmero, Ramon
    Carlos Ruffinelli, Jose
    Navarro, Arturo
    Dolores Arnaiz, Maria
    Brao, Isabel
    Aso, Samantha
    Padrones, Susana
    Cardenal, Felipe
    Nadal, Ernest
    BMC CANCER, 2019, 19 (1)